These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33880062)

  • 1. Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis.
    Vyas A; Gabriel M; Kurian S
    Breast Cancer (Dove Med Press); 2021; 13():259-269. PubMed ID: 33880062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States.
    Vyas AM; Aroke H; Kogut S
    J Natl Compr Canc Netw; 2020 Apr; 18(4):405-413. PubMed ID: 32259787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of guideline-concordant initial systemic treatment with clinical and economic outcomes among older women with metastatic breast cancer in the United States.
    Vyas A; Mantaian T; Kamat S; Kurian S; Kogut S
    J Geriatr Oncol; 2021 Sep; 12(7):1092-1099. PubMed ID: 34099411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Poorvu PD; Vaz-Luis I; Freedman RA; Lin NU; Barry WT; Winer EP; Hassett MJ
    Breast Cancer Res Treat; 2018 Apr; 168(3):727-737. PubMed ID: 29332137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
    Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors Associated With Guideline-Concordant Pharmacological Treatment for Neuropathic Pain Among Breast Cancer Survivors.
    Lakkad M; Martin B; Li C; Harrington S; Dayer L; Painter JT
    Clin Breast Cancer; 2023 Aug; 23(6):598-619. PubMed ID: 37328334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer.
    Williams CP; Azuero A; Kenzik KM; Pisu M; Nipp RD; Bhatia S; Rocque GB
    J Natl Compr Canc Netw; 2019 Oct; 17(10):1221-1228. PubMed ID: 31590153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
    Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
    Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
    Brufsky A; Liu X; Li B; McRoy L; Layman RM
    Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
    Goyal RK; Carter GC; Nagar SP; Smyth EN; Price GL; Huang YJ; Li L; Davis KL; Kaye JA
    Curr Med Res Opin; 2019 Oct; 35(10):1699-1710. PubMed ID: 31060392
    [No Abstract]   [Full Text] [Related]  

  • 13. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
    Gilbert A; Williams C; Azuero A; Burkard ME; Kenzik K; Garrett-Mayer E; Meersman S; Rocque G
    Clin Breast Cancer; 2021 Aug; 21(4):292-301. PubMed ID: 33309481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receipt of Guideline-Concordant Care Among Older Women With Stage I-III Breast Cancer: A Population-Based Study.
    LeMasters T; Madhavan SS; Sambamoorthi U; Hazard-Jenkins HW; Kelly KM; Long D
    J Natl Compr Canc Netw; 2018 Jun; 16(6):703-710. PubMed ID: 29891521
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers.
    Wu XC; Lund MJ; Kimmick GG; Richardson LC; Sabatino SA; Chen VW; Fleming ST; Morris CR; Huang B; Trentham-Dietz A; Lipscomb J
    J Clin Oncol; 2012 Jan; 30(2):142-50. PubMed ID: 22147735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receipt of guideline-concordant treatment in elderly prostate cancer patients.
    Chen RC; Carpenter WR; Hendrix LH; Bainbridge J; Wang AZ; Nielsen ME; Godley PA
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):332-8. PubMed ID: 24411605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer.
    Williams CP; Kenzik KM; Azuero A; Williams GR; Pisu M; Halilova KI; Ingram SA; Yagnik SK; Forero A; Bhatia S; Rocque GB
    Oncologist; 2019 Jan; 24(1):31-37. PubMed ID: 30120157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
    Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
    Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.